ADCYAP1R1 and atherosclerosis: Therefore, we tested the PAC1 receptor agonist Maxadilan and the PAC1 selective antagonist M65 on plaque development and lumen stenosis in the ApoE−/− atherosclerosis model for possible effects on atherogenesis.